March 27, 2015
Leuven, Belgium - March 27, 2015
Based on the current information it disposes of, the Belgian Federal Agency for Medicines and Health Products (FAMHP) advises not to suspend nor stop any treatments involving Terumo injection needles.
On March 25, the Terumo production site of Leuven received an inspection of the Belgian Federal Agency for Medicines and Health Products (FAMHP). After a first analysis of the issue and based on the information they currently dispose of, the FAMHP advises patients not to suspend nor stop any treatments with Terumo injection needles.
"We have cooperated with FAMHP in full transparency during the inspection at our Leuven production site. We will continue to closely work with the authorities in the following weeks, as patient safety and the highest quality standards always come first at Terumo," concludes Kyo Nishikawa, Managing Director Terumo Europe.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.